Pharmacokinetic profile of PBRM in rodents, a first selective covalent inhibitor of 17β-HSD1 for breast cancer and endometriosis treatments

René Maltais; Alexandre Trottier; Jenny Roy; Diana Ayan; Diana Ayán; Nicolas Bertrand; Donald Poirier

doi:10.1016/j.jsbmb.2017.12.007

Pharmacokinetic profile of PBRM in rodents, a first selective covalent inhibitor of 17β-HSD1 for breast cancer and endometriosis treatments

René Maltais, Alexandre Trottier, Jenny Roy, Diana Ayan, Diana Ayán, Nicolas Bertrand, Donald Poirier

The Journal of steroid biochemistry and molecular biology · 2017 · vol. 178 , pp. 167–176 · doi:10.1016/j.jsbmb.2017.12.007 · PMID:29248731 · W2771931566

article OA: closed CC0 ⤵ 5 in-corpus citations

Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".

View at publisher → View on OpenAlex View on PubMed

⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study characterized the pharmacokinetic profile of PBRM, a novel selective covalent inhibitor of 17β-HSD1, in rodents as a potential therapeutic for breast cancer and endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Benzamides Breast Neoplasms Endometriosis Enzyme Inhibitors Estradiol Dehydrogenases Animals Apoptosis Benzamides Benzamides Benzamides Breast Neoplasms Breast Neoplasms Breast Neoplasms Cell Proliferation Endometriosis Endometriosis Endometriosis Enzyme Inhibitors Enzyme Inhibitors Estradiol Dehydrogenases

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (30)

Design and validation of specific inhibitors of 17 -hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis via openalex
doi:10.1002/anie.201601091 via openalex
doi:10.18632/oncotarget.15547 via openalex
doi:10.1021/jacs.6b08656 via openalex
doi:10.1517/13543776.2010.505604 via openalex
doi:10.1016/j.bcp.2017.08.004 via openalex
doi:10.1021/ml200093v via openalex
doi:10.1016/j.jsbmb.2010.12.013 via openalex
doi:10.1016/j.bmc.2014.09.026 via openalex
doi:10.1002/cmdc.201500469 via openalex
doi:10.1158/0008-5472.can-04-3714 via openalex
doi:10.1021/jm401639v via openalex
doi:10.1016/j.bmcl.2013.10.003 via openalex
doi:10.1080/03602530600952172 via openalex
doi:10.1158/1535-7163.mct-12-0299 via openalex
doi:10.1016/j.canlet.2004.10.007 via openalex
doi:10.1016/j.mce.2013.07.026 via openalex
doi:10.1016/j.jsbmb.2015.10.020 via openalex
doi:10.1038/nrd1329 via openalex
doi:10.1016/j.steroids.2004.03.002 via openalex
doi:10.1210/jc.2011-2994 via openalex
doi:10.1042/bj20091020 via openalex
doi:10.1203/00006450-196705000-00005 via openalex
doi:10.1517/17460441.2012.688744 via openalex
doi:10.1016/j.mce.2008.08.026 via openalex
doi:10.2174/15680266113139990004 via openalex
doi:10.1517/17425255.2.6.875 via openalex
doi:10.1038/nrd3410 via openalex
doi:10.1016/j.jsbmb.2006.02.004 via openalex
doi:10.2165/00003088-197601030-00003 via openalex

Cited by (5)

Source provenance

europepmc: last seen: 2026-06-21T06:12:49.409960+00:00
openalex: last seen: 2026-05-11T06:15:24.675520+00:00
pubmed: last seen: 2026-05-13T22:20:07.505861+00:00
unpaywall: last seen: 2026-06-20T06:35:16.286784+00:00

License: CC0 · commercial use OK

[1] Design and validation of specific inhibitors of 17 -hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis via openalex

[2] doi:10.1002/anie.201601091 via openalex

[3] doi:10.18632/oncotarget.15547 via openalex

[4] doi:10.1021/jacs.6b08656 via openalex

[5] doi:10.1517/13543776.2010.505604 via openalex

[6] doi:10.1016/j.bcp.2017.08.004 via openalex

[7] doi:10.1021/ml200093v via openalex

[8] doi:10.1016/j.jsbmb.2010.12.013 via openalex

[9] doi:10.1016/j.bmc.2014.09.026 via openalex

[10] doi:10.1002/cmdc.201500469 via openalex

[11] doi:10.1158/0008-5472.can-04-3714 via openalex

[12] doi:10.1021/jm401639v via openalex

[13] doi:10.1016/j.bmcl.2013.10.003 via openalex

[14] doi:10.1080/03602530600952172 via openalex

[15] doi:10.1158/1535-7163.mct-12-0299 via openalex

[16] doi:10.1016/j.canlet.2004.10.007 via openalex

[17] doi:10.1016/j.mce.2013.07.026 via openalex

[18] doi:10.1016/j.jsbmb.2015.10.020 via openalex

[19] doi:10.1038/nrd1329 via openalex

[20] doi:10.1016/j.steroids.2004.03.002 via openalex

[21] doi:10.1210/jc.2011-2994 via openalex

[22] doi:10.1042/bj20091020 via openalex

[23] doi:10.1203/00006450-196705000-00005 via openalex

[24] doi:10.1517/17460441.2012.688744 via openalex

[25] doi:10.1016/j.mce.2008.08.026 via openalex

[26] doi:10.2174/15680266113139990004 via openalex

[27] doi:10.1517/17425255.2.6.875 via openalex

[28] doi:10.1038/nrd3410 via openalex

[29] doi:10.1016/j.jsbmb.2006.02.004 via openalex

[30] doi:10.2165/00003088-197601030-00003 via openalex